Your browser doesn't support javascript.
loading
The inequity of targeted cystic fibrosis reproductive carrier screening tests in Australia.
Shum, Bennett O V; Sng, Letitia M F; Ruseckaite, Rasa; Henner, Ilya; Twine, Natalie; Bauer, Denis C; Wilgen, Urs; Pretorius, Carel; Barahona, Paulette; Ungerer, Jacobus P J; Bennett, Glenn.
Afiliação
  • Shum BOV; Preventive Health Division, Genepath, Sydney, New South Wales, Australia.
  • Sng LMF; EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of NSW, New South Wales, Sydney, Australia.
  • Ruseckaite R; Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Sydney, New South Wales, Australia.
  • Henner I; Applied BioSciences, Faculty of Science and Engineering, Macquarie University, Sydney, New South Wales, Australia.
  • Twine N; Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Bauer DC; Preventive Health Division, Genepath, Sydney, New South Wales, Australia.
  • Wilgen U; Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Sydney, New South Wales, Australia.
  • Pretorius C; Applied BioSciences, Faculty of Science and Engineering, Macquarie University, Sydney, New South Wales, Australia.
  • Barahona P; Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Sydney, New South Wales, Australia.
  • Ungerer JPJ; Applied BioSciences, Faculty of Science and Engineering, Macquarie University, Sydney, New South Wales, Australia.
  • Bennett G; Department of Biomedical Sciences, Faculty of Medicine and Health Science, Macquarie University, Sydney, New South Wales, Australia.
Prenat Diagn ; 43(1): 109-116, 2023 01.
Article em En | MEDLINE | ID: mdl-36484552
ABSTRACT

OBJECTIVE:

European and Australian guidelines for cystic fibrosis (CF) reproductive carrier screening recommend testing a small number of high frequency CF causing variants, rather than comprehensive CFTR sequencing. The study objective was to determine variant detection rates of commercially available targeted reproductive carrier screening tests in Australia.

METHODS:

Next-generation DNA sequencing of the CFTR gene was performed on 2552 individuals from a whole population sample to identify CF causing variants. The variant detection rates of two commercially available Australian reproductive carrier screening tests, which target 50 or 175 CF causing variants, in this population were calculated. The ethnicity of individuals was determined using principal component analysis.

RESULTS:

Variant detection rates of the tests for 50 and 175 CF causing variants were 88.2% and 90.8%, respectively. No CF causing variants in individuals of East Asian ethnicity (n = 3) were detected by either test, while >86.6% (n = 69) of CF causing variants in Europeans would be identified by either test.

CONCLUSIONS:

Reproductive carrier screening tests for a targeted set of high frequency CF variants are unable to detect approximately 10% of CF variants in a multiethnic Australian population, and individuals of East Asian ethnicity are disproportionally affected by this test limitation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Cística Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Prenat Diagn Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Cística Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Prenat Diagn Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália